THR-184

DB19097InvestigationalProtein Based Therapies

THR-184 is under investigation in clinical trial NCT01830920 (A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-acute Kidney Injury (CSA-AKI)).

Mechanism: Pharmacologically active on Bone morphogenetic protein receptor type-1A
Curator reviewed
Also known as: L-CYSTEINYL-L-TYROSYL-L-TYROSYL-L-.ALPHA.-ASPARTYL-L-ASPARAGINYL-L-SERYL-L-SERYL-L-SERYL-L-VALYL-L-LEUCYL-L-CYSTEINYL-L-LYSYL-L-ARGINYL-L-TYROSYL-L-ARGINYL-L-SERINE
Code names: THR-184

Resolves to

Compound

UNII616BV6U9G8CAS930274-80-9

Targets

P36894BMPR1A

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with THR-184, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account